Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study

Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study TANGUY-SCHMIDT, Aline, et al. We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Imatinib-based strategy improved the 4-year overall survival (OS) up to 52 % versus 20 % in the pre-imatinib LALA-94 trial (P =.0001). Despite the selection in patients who actually underwent transplantation, these results suggest that allogeneic or autologous stem cell transplants (SCTs) still have a place in overcoming the poor prognosis of Ph+ ALL in the era of imatinib therapy. OS was 50 % after allogeneic SCT (24 patients), 33 % in patients without a transplantation (9 patients), and 80 % after autologous SCT (10 patients without allogeneic donor or>55 years, including 7 patients in complete molecular response). TANGUY-SCHMIDT, Aline, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblasti